An all-oral regimen for older adults with acute myeloid leukemia moved into focus after results from the ASCERTAIN V trial. The phase 1/phase 2 study is designed to reduce the logistical burden of conventional AML care, which typically requires frequent hospital visits for intravenous chemotherapy—an issue that often limits access for frail populations. The trial expands the pipeline for outpatient-capable AML approaches by testing whether an oral strategy can deliver meaningful clinical activity while maintaining tolerability. The report frames the study as an effort to address real-world constraints that affect adherence and treatment continuity. While detailed efficacy and safety outcomes are not fully included in the summary provided, the core development is the move toward an oral-only treatment platform in a setting where treatment intensity and complexity are major barriers. Industry attention will likely center on how durability compares with standard-of-care and whether the regimen can be integrated into existing care pathways for older and medically unfit patients.